Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycium barbarum polysaccharides (LBP) are the primary bioactive components extracted from the fruit of *Lycium barbarum* L., commonly known as goji berry or wolfberry. [1] They are water-soluble glycoconjugates investigated for a wide range of therapeutic effects, including neuroprotection, immunomodulation, antioxidant, anti-inflammatory, and metabolic regulation. [1, 10] In preclinical models of glaucoma, LBP has demonstrated neuroprotective effects on retinal ganglion cells by modulating the endothelin system (down-regulating ET-1 and regulating its ETA and ETB receptors), which may improve retinal blood supply. [19, 4] In gastrointestinal and metabolic disorders, its mechanism involves modulating the gut microbiota by promoting beneficial bacteria and influencing the production of short-chain fatty acids. [7, 15, 18] Clinical trials are investigating LBP for conditions such as type 2 diabetes, cancer-related fatigue, colorectal cancer, and non-alcoholic fatty liver disease (NAFLD). [5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lycium barbarum polysaccharides.